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The protective action of quercetin against the pro-oxi-
dant and apoptotic effect of etoposide was investigat-
ed in HL-60 cells with a high level of myeloperoxidase 
(MPO) activity and in cells treated with MPO inhibitor, 
4-aminobenzoic acid hydrazide (ABAH). Quercetin signifi-
cantly protected MPO-rich cells against the pro-oxidative 
(p<0.05) and apoptotic (p<0.05) effects of etoposide. Pre-
treatment with ABAH abolished this protective influence 
of quercetin on apoptosis induced by etoposide but ac-
tually enhanced the action effect of quercetin against 
etoposide-generated reactive oxygen species (ROS) level 
by this cytostatic drug. Thus quercetin can protect HL-60 
cells against the pro-oxidative activity of etoposide re-
gardless of MPO activity.
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INTRODUCTION
Etoposide is a first-line anticancer drug used in the 
treatment of certain solid tumours, lymphomas and 
leukemias (Slevin, 1991). In normal bone marrow cells, 
etoposide can initiate carcinogenesis leading to the devel-
opment of myeloid leukemia, which occurs in a few per-
centage of patients (Whitlock et al., 1991). On the other 
hand, the most common side effect induced by etopo-
side is myelosuppression, which limits its use (Kobayashi 
& Ratain, 1994).
Currently, a major role in the cancerogenic action of 
etoposide is assigned to its radicals formed in the pre-
cursor myeloid cells, probably mainly owing to the ac-
tion of myeloperoxidase (MPO) (Kagan et al., 1999; Fan 
et al., 2006). Studies with the use of cyanide and azide, 
which are inhibitors of MPO, have demonstrated that 
etoposide undergoes one-electron oxidation to phenoxyl 
radicals by MPO in leukemic promyelocytic HL-60 cells 
and human myeloid progenitor CD34+ cells (Kagan et 
al., 1999; Vlasova et al., 2011). Studies on HL-60 cells 
have also confirmed that the etoposide redox-cycling 
catalyzed by MPO involves intracellular reducing agents, 
mainly reduced glutathione (GSH), leading to the oxida-
tion of thiols and the formation of thiyl radicals (Ka-
gan et al., 1999). Because of further reactions involving 
thiyl radicals, oxygen radicals may arise, including the 
highly toxic hydroxyl radical. In addition, the action of 
genotoxic etoposide radicals may include the oxidation 
of topoisomerase II, because incubation of HL-60 cells 
with ascorbate leads to a decrease in the level of these 
radicals and also reduces the amount of etoposide-topo 
II-DNA adducts (Kagan et al., 1999).
The oxidative stress caused by toxic etoposide radicals 
may enhance oxidative DNA damage and topoisomerase 
II-dependent recombination (Vlasova et al., 2011). In ad-
dition, DNA damage leads to apoptosis and the inhibi-
tion of proliferation, and is partly responsible for myelo-
suppression.
Thus, reduction of the radicals produced during the 
oxidation of etoposide in precursor cells of the myeloid 
lineage could contribute to both an increase in the ap-
plicable dosage of etoposide and enhanced therapeutic 
results while minimizing the side effects of treatment. It 
is known that treatment of HL-60 cell homogenates with 
an MPO inhibitor or antioxidants such as ascorbate re-
duces the formation of etoposide phenoxyl radicals (Ka-
gan et al., 1999). However, ascorbate is rapidly consumed 
in the reaction and not adequately protects against the 
pro-oxidative action of etoposide (Kagan et al., 1999).
Polyphenols, such as quercetin can limit the pro-oxi-
dant and cytogenotoxic action of etoposide more effec-
tively than classical antioxidants. Quercetin exerts antiox-
idant activity via a variety of mechanisms, such as scav-
enging free radicals, chelating transition metal ions and 
inducing the antioxidant defence system regulated by nu-
clear factor erythroid 2-related factor 2 (Nrf2) (Hu et al., 
1995; Cheng & Breen, 2000; Ramyaa et al., 2014). Given 
that quercetin can also inhibit the activity of MPO and 
CYP3A4 (Pincemail et al., 1988; Kagan et al., 1999; Choi 
et al., 2011; Jacob et al., 2011) an even more effective 
action of this flavonoid in reducing the side effects of 
etoposide could be expected than is the case with con-
ventional antioxidants.
Previously, it has been demonstrated that the antiox-
idant quercetin can protect mature granulocytes against 
the formation of phenoxyl etoposide radicals and apop-
tosis induced by this cytostatic drug (Kapiszewska et al., 
2007). So far, there has been no research into whether 
quercetin can modify the action of etoposide in myeloid 
cells in a manner dependent on the activity of MPO.
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The aim of this study was to determine the effect of 
quercetin on the apoptotic and pro-oxidant action of 
etoposide in HL-60 cells with a high MPO activity and 
in cells treated with an MPO inhibitor.
MATERIAL AND METHODS
HL-60 cell culture conditions. HL-60 cell line was 
purchased from ATCC (American Type Cell Culture, 
UK). The cells were cultured in RPMI 1640 (ATCC, 
UK) supplemented with 10% fetal bovine serum (FBS, 
Sigma-Aldrich, St. Louis, MO, USA), without antibiotics, 
and in standard conditions at 37°C in a 5% CO2 and 
95% humidified atmosphere. The cells in the logarithmic 
growth phase were seeded in 24-well culture plates at a 
density of 0.5 × 106 cells/well.
Treatment of the cells. The cells were preincubated 
with 100 mM 4-aminobenzoic acid hydrazide (ABAH) 
for 24 hours followed by incubation in the presence of 
different concentrations of quercetin (0.5–50 mM) and/
or etoposide (1–10 mM) for 24 hours. ABAH was dis-
solved in RPMI and other compounds in dimethyl sul-
foxide (DMSO) and subsequently diluted in PBS. Final 
concentration of DMSO did not exceed 1% in the cul-
ture medium. Reagents were purchased from Sigma-Al-
drich, St. Louis, Missouri, USA. Control cells were in-
cubated in the presence of DMSO. The experiment was 
repeated three times.
Cytochemical staining for MPO. MPO activity 
in the cells was detected using 4-chloro-1-naphthol kit 
(Merck KgaA, Darmstadt, Germany) according to manu-
facturer’s instruction. The cytochemical reaction is based 
on the oxidation of 4-chloro-1-naphthol which is con-
verted to a black brownish insoluble dye. The intensity 
of staining is proportional to MPO activity.
ROS measurements. Reactive oxygen species (ROS) 
were detected in the cells using 5-(and-6′)-chloromethyl-
2′,7′-dichlorodihydrofluorescein diacetate (CM-H2DCF-
DA, Life Science Technology) staining. Acetate groups 
of CM-H2DCFDA are cleaved by intracellular esterases 
to non fluorescent dichlorofluorescein (DCFH) which 
reacts with intracellular antioxidants like glutathione 
and other thiols. DCFH undergoes rapid oxidation un-
der the influence of ROS to a fluorescent dye with Ex/
Em of 502/523 nm. Briefly, HL-60 cells were incubated 
with quercetin (0.5–100 µM) and/or etoposide (1–10 
µM) for 1 hour. After incubation, the cells were washed 
with Hank’s balanced salt solution (HBSS, Life Science 
Technology) and incubated with 10 µM CM-H2DCF-
DA in 1 ml HBSS for 30 min in the dark. Then, they 
were washed with cold HBSS and suspended with 400 
µl of this buffer and quickly analyzed. The intensity of 
fluorescence was measured in an LSR II flow cytometer 
(Becton Dickinson, BD Biosciences Immunocytometry 
Systems, San Jose, CA, USA) equipped with a blue laser 
(488 nm excitation, 575/26 BP filter). Histograms were 
analyzed using FACSDiva software. Doublets were ex-
cluded from the analysis using gating on width versus 
area of the forward scatter (FSC) and side scatter (SSC). 
The analysis was performed on at least 20 000 events.
Analysis of apoptosis. The cells were incubated with 
quercetin (0.5–1 µM) and/or etoposide (10 µM) for 24 
hours. After incubation, the cells were washed (230 × g, 
10 min) and resuspended in hydroxyethyl pipera-
zineethanesulfonic acid (HEPES) binding buffer (Becton 
Dickinson). The cells were incubated with 2 µl of An-
nexin V-allophycocyanin (APC) (Becton Dickinson) and 
2 µl of propidium iodide (PI, 50 μg/ml, Sigma-Aldrich) 
per 50 µl of HEPES for 15 min in the dark. Then, they 
were suspended in 400 µL HEPES (Sigma-Aldrich) and 
analyzed in an LSR II flow cytometer equipped with 
red and blue lasers, using 633 nm excitation for APC 
(660/20 BP filter) and 488 nm excitation for PI (575/26 
BP filter). The percentages of early apoptotic (annexin 
V-APC-positive/PI-negative), necrotic (annexin-APC-
negative/PI-positive) and late apoptotic cells (annexin-
APC-positive/PI-positive) were analyzed using FACSDi-
va software (Becton Dickinson). Doublets were excluded 
from analysis using gating on width versus area of the 
forward scatter (FSC) and side scatter (SSC). Analysis 
was performed on at least 20 000 events.
Cell cycle analysis. The cells were incubated with 
quercetin (0.5 or 1 µM) and/or etoposide (10 µM) for 
24 hours. After incubation, the cells (1 × 106 cells) were 
washed with PBS and fixed in 70% ethanol at –20°C for 
24 hours. After fixation, the cells were washed in PBS 
and incubated for 30 min in 0.5 ml of solution contain-
ing 0.1% Triton X-100, 40 mg/ml RNAse A and 2% PI. 
The cell cycle was analyzed in an LSR II flow cytometer. 
Analysis was performed on at least 20 000 events.
Statistical analysis. Values are expressed as means 
± SD. Student’s t-test and one-way analysis of variance 
followed by Newman-Keuls and Tukey post hoc tests 
were used to determine significant differences (p<0.05) 
between samples.
Figure 1. ROS accumulation in HL-60 cells treated with etoposide (a) and quercetin (b). 
The cells were incubated with increasing concentrations of quercetin and etoposide. ROS levels were evaluated using staining with 
CM-H2DCFDA. The analysis was performed by flow cytometry. RFU — relative fluorescence units. C — control, Q — quercetin, E — eto-
poside. Data are presented as mean ± S.D. of the mean. *p<0.05, **p<0.01, ***p<0.001.
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RESULTS AND DISCUSSION
Quercetin, as an antioxidant, can interrupt the redox 
cycle of etoposide by reducing the amount of phenoxyl 
radicals in cells. The present results indicate that querce-
tin can protect human myeloid cells with high MPO 
activity against the pro-oxidant and apoptotic effects of 
etoposide.
High concentrations of quercetin (50–200 µM) po-
tentiate the cytotoxic effects of chemotherapy in vitro 
(Samuel et al., 2012). However, less is known about the 
effect of low concentrations of this flavonoid on the ac-
tion of chemotherapeutic agents. In this study quercetin 
concentrations of 0.5 and 1 µM were selected based on 
reports that the use of this flavonoid in concentrations 
below 6 µM can protect HCT116 p53-null cells against 
the effects of 5-fluorouracil in vitro (Samuel et al., 2012). 
In addition, low concentrations of quercetin (0.5–5 µM) 
are achievable in blood plasma (Wiczkowski et al., 2008).
The present study proved that etoposide can act as a 
pro-oxidant in dose dependent manner toward different 
intracellular constituents in HL-60 cells (Fig. 1a). How-
ever, cell pre-treatment with ABAH a selective inhibitor 
of MPO significantly reduced the level of ROS generat-
ed by etoposide (10 µM) (Fig. 2a, b). Quercetin protect-
ed HL-60 cells even more effectively than ABAH against 
the pro-oxidant action of etoposide (Fig. 2b). This fact 
indicates the different contribution of the pro-oxidative 
metabolism of etoposide than that of the oxidation of 
etoposide by MPO. ABAH, significantly reduced the ac-
tivity of this enzyme in HL-60 cells, when used at a con-
centration of 100 µM (Fig. 2c).
Furthermore, it can be seen that quercetin alone re-
duces the amount of free radicals in HL-60 cells com-
pared to the control (Fig. 1b). Quercetin may therefore 
reduce endogenous levels of free radicals produced as 
a result of various intracellular redox-cycling reactions, 
which are usually elevated in neoplastic cells. This fla-
vonoid can inhibit both prostaglandin synthase and 
CYP3A4 cytochrome, contributing to reduced levels of 
etoposide catechol metabolites which can be oxidized by 
MPO and other enzymes capable of producing superox-
ide (Bender et al., 2004; Moon et al., 2006; Choi et al., 
2011).
 It has been demonstrated in a cell-free system that 
etoposide quinones induce far more DNA strand breaks 
associated with the activity of topoisomerase II than 
their parent drug. Also, etoposide catechols are stronger 
topoisomerase II poisons (Gantchev & Hunting, 1998; 
Lovett et al., 2001). Quinone and catechols of etoposide 
may increase the genotoxic action of the parent drug 
leading to an increase in the DNA double-strand breaks 
(DSBs), which are one of the most deleterious forms of 
DNA damage, resulting in further consequences such as 
cell cycle arrest and apoptosis (Karanjawala et al., 2002). 
The cell cycle suppression and apoptosis of normal pro-
liferating hematopoietic precursors can result in myelo-
suppression.
Protective effect of quercetin may also consist in 
quercetin competing with etoposide to be a substrate of 
MPO and thereby preventing it from entering the re-
dox-cycling reactions. Importantly, quercetin exerted its 
protective effect already at a concentration of 0.5 μM, 
a level which may occur in the blood plasma following 
Figure 2. The influence of quercetin on ROS level generated under the action of etoposide in HL-60 cells with normal or decreased 
activity of MPO. 
The cells were pretreated or not with 100 µM ABAH followed by incubation with quercetin (0.5 or 1 μM) and/or etoposide (10 μM). ROS 
accumulation was detected using staining with CM-H2DCFDA. The analysis was performed by flow cytometry. (a) Representative histo-
grams of fluorescence (b) RFU — relative fluorescence units. Data are presented as mean ± S.D. of the mean. Means having different 
signs (a, b, c) differ significantly, p<0.05. (c) Cytochemical reaction for MPO activity in control and ABAH-treated cells. C — control, Q — 
quercetin, E — etoposide.
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ingestion of this flavonoid. It is worth nothing that in 
other studies quercetin at the same concentration of 0.5 
μM induced a significant increase in the proliferation of 
HeLa cells (Spagnuolo et al., 2012).
In comparison to the control, etoposide at a concen-
tration of 10 µM significantly increased the percentage of 
late apoptotic cells (annexin V+/PI+) and the sub-G1 
fraction corresponding to apoptotic cells (Fig. 3a, Ta-
ble 1) but did not affect the percentages of early apop-
totic or necrotic cells (data not shown). Pretreatment 
with ABAH decreased the level of etoposide-induced 
late apoptosis non-significantly. In contrast, quercetin 
significantly decreased the fraction of late apoptotic cells 
and sub-G1 fraction induced by etoposide. However, ad-
ditional pretreatment with ABAH did not enhance the 
protective effect of quercetin against apoptosis induced 
by etoposide (Fig. 3a, b, Table 1).
Etoposide arrested the cell cycle in the S phase, and 
quercetin and ABAH failed to significantly modify the 
action of this chemotherapeutic agent (Table 1).
In the presence of MPO, when etoposide radicals are 
formed, quercetin acts as an antioxidant, reducing the 
level of free radicals generated by etoposide and decreas-
ing the extent of apoptosis induced by this chemother-
apeutic agent. In this manner, quercetin can contribute 
to reducing the cytotoxic effects of etoposide in bone 
marrow cells. After inhibiting the pro-oxidative effect 
of MPO using ABAH, quercetin did not protect cells 
against the cytotoxic action of etopo-
side. It is known from other studies 
that quercetin can suppress the cell cy-
cle and induce the apoptosis of leuke-
mic cells. Also, it can induce apoptosis 
by reducing AKT, BCL-2, BAX and 
increasing the level of caspase activa-
tion (Yuan et al., 2012).
Reactive intermediates produced 
during the metabolism of chemo-
therapeutic drugs can lead directly to 
DSBs (Kagan et al., 1999; Sallmyr et 
al., 2008). Unrepaired DSBs can cause 
apoptosis or, in the case of disrupted 
apoptotic pathways, promote mutagen-
esis. Our earlier study has demonstrat-
ed that quercetin can protect myeloid 
cells against etoposide-induced DSBs 
in vitro and in vivo (Papież, 2014). In 
the present study, the protective an-
Figure 3. The influence of quercetin on the fraction of late apoptotic cells induced by etoposide in HL-60 cells with normal or de-
creased activity of MPO. 
The cells were pretreated or not with 100 µM ABAH followed by incubations with quercetin (0.5 or 1 μM) and/or etoposide (10 μM). 
Apoptosis was analyzed by flow cytometry. (a) Data are presented as mean ± S.D. of the mean. Means having different signs (a, b, c , d) 
differ significantly, p<0.05. (b) Representative dot plots. C — control, Q — quercetin, E — etoposide.
Table 1. Cell cycle in HL-60 cells treated with quercetin and/or etoposide. 
The cells were pretreated or not with 100 µM ABAH followed by incubations with quer-
cetin (0.5 or 1 μM) and and/or etoposide (10 μM). Data are presented as mean ± S.D. of 
the mean. Values marked with different letters (a, b, c) in the same column differ signifi-
cantly, p<0.05. Q — quercetin, E — etoposide.
Treatment of cells sub-G1 G1 S G2/M
Control 3.3±0.6a 58.0±0.5a 23.8±0.2a 14.7±1.1a
ABAH 3.1±0.4a 54.7±2.6a 24.7±0.7a 17.3±2.2a
E  21.4±1.6b 44.2±1.1b 28.4±1.1b 5.7±0.6b
E + ABAH  19.7±1.2b 45.8±3.1b 28.3±2.6b 6.4±1.3b
E + Q 0.5 µM  18.3±0.5c 45.2±1.5b 30.0±0.6b 6.3±1.0b
E + Q 0.5 µM + ABAH  18.5±1.4c 47.2±2.9b 28.7±1.7b 6.1±0.9b
E + Q 1 µM  19.4±1.0b,c 44.4±2.1b 29.1±1.5b 6.9±0.8b
E + Q 1 µM + ABAH  19.6±1.0b,c 45.6±4.7b 27.9±1.9b 6.7±1.9b
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tioxidant effect of low concentrations of quercetin cor-
related with its anti-apoptotic action. It can be assumed 
that the antioxidant quercetin should prevent apoptosis 
and DNA damage in myeloid precursor cells during 
etoposide therapy.
The present study demonstrates for the first time that 
quercetin can limit the pro-oxidant and apoptotic ac-
tion of etoposide in human myeloid precursor cells with 
high levels of MPO activity and, at concentrations of 0.5 
or 1 µM, it may act more strongly than an inhibitor of 
this enzyme. On the other hand, if quercetin can pro-
tect leukemia cells against etoposide action, it would be 
necessary to conduct further research in order to clar-
ify whether the dosages of this flavonoid achievable in 
blood plasma will not limit the antileukemic activity of 
this cytostatic drug. The antagonistic effect on chemo-
therapeutic agents of another antioxidant, vitamin C, is 
known from in vitro studies (Samuel et al., 2012).
Acknowledgements
This study was supported by the Jagiellonian Univer-
sity Programs No. K/ZDS/004679.
REFERENCES
Bender RP, Lindsey RH, Burden DA, Osheroff N (2004) N-acetyl-p-
benzoquinone imine, the toxic metabolite of acetaminophen is a 
topoisomerase II poison. Biochemistry 43: 3731–3739.
Cheng IF, Breen K (2000) On the ability of four flavonoids, baicilein, 
luteolin, naringenin, and quercetin, to suppress the Fenton reaction 
of the iron-ATP complex. Biometals 13: 77-83.
Choi JS, Piao YJ, Kang KW (2011) Effects of quercetin on the bio-
availability of doxorubicin in rats: role of CYP3A4 and P-gp inhibi-
tion by quercetin. Arch Pharm Res 34: 607-613.
Fan Y, Schreiber EM, Giorgianni A, Yalowich JC, Day BW (2006) 
Myeloperoxidase-catalyzed metabolism of etoposide to its quinone 
and glutathione adduct forms in HL60 cells. Chem Res Toxicol 19: 
937–943.
Gantchev TG, Hunting DG (1998) The ortho-quinone metabolite of 
the anticancer drug etoposide (VP-16) is a potent inhibitor of the 
topoisomerase II/DNA cleavable complex. Mol Pharmacol 53: 422-
428.
Hu JP, Calomme M, Lasure A, De Bruyne T, Pieters L, Vlietinck A, 
Vanden Berghe DA (1995) Structure-activity relationships of fla-
vonoids with superoxide scavenging ability. Biol Trace Elem Res 47: 
327–331.
Jacob DA, Mercer SL, Osheroff N, Deweese JE (2011) Etoposide qui-
none is a redox-dependent topoisomerase ii poison. Biochemistry 50: 
5660–5667.
Kagan VE, Yalowich JC, Borisenko GG, Tyurina YY, Tyurin VA, 
Thampatty P, Fabisiak JP (1999) Mechanism-based chemopreventi-
ve strategies against etoposide-induced acute myeloid leukemia: free 
radical/antioxidant approach. Mol Pharmacol 56: 494–506.
Kapiszewska M, Cierniak A, Elas M, Lankoff A (2007) Lifespan of 
etoposide-treated human neutrophils is affected by antioxidant abili-
ty of quercetin. Toxicology in Vitro 21: 1020–1030.
Karanjawala ZE, Murphy N, Hinton DR, Hsieh CL, Lieber MR (2002) 
Oxygen metabolism causes chromosome breaks and is associated 
with the neuronal apoptosis observed in DNA doublestrand break 
repair mutants. Curr Biol 12: 397–402.
Kobayashi K, Ratain MJ (1994) Pharmacodynamics and long-term tox-
icity of etoposide. Cancer Chemoth Pharm 34: S64–S68.
Lovett BD, Strumberg D, Blair IA, Pang S, Burden DA, Megonigal 
MD, Rappaport EF, Rebbeck TR, Osheroff N, Pommier YG, Felix 
CA (2001) Etoposide metabolites enhance DNA topoisomerase II 
cleavage near leukemia-associated MLL translocation breakpoints. 
Biochemistry 40: 1159–1170.
Moon YJ, Wang X, Morris ME (2006) Dietary flavonoids: effects on 
xenobiotic and carcinogen metabolism. Toxicol In Vitro 20: 187–210.
Papież MA (2014) The effect of quercetin on oxidative DNA damage 
and myelosuppression induced by etoposide in bone marrow cells 
of rats. Acta Biochim Pol 61: 7-11.
Pincemail J, Deby C, Thirion A, de Bruyn-Dister M, Goutier R (1988) 
Human myeloperoxidase activity is inhibited in vitro by quercetin. 
Comparison with three related compounds. Experientia 44: 450-453.
Ramyaa P, Krishnaswamy R, Padma VV (2014) Quercetin modulates 
OTA-induced oxidative stress and redox signalling in HepG2 cells 
— up regulation of Nrf2 expression and down regulation of NF-κB 
and COX-2. Biochim Biophys Acta 1840: 681-92.
Sallmyr A, Fan J, Rassool FV (2008) Genomic instability in myeloid 
malignancies: increased reactive oxygen species (ROS), DNA double 
strand breaks (DSBs), and error-prone repair. Cancer Lett 270: 1–9.
Samuel T, Fadlalla K, Mosley L, Katkoori V, Turner T, Manne U 
(2012) Dual-mode interaction between quercetin and dna-damaging 
drugs in cancer cells. Anticancer Res 32: 61–71.
Slevin ML (1991) The clinical pharmacology of etoposide. Cancer 67: 
319–329.
Spagnuolo C, Russo M, Bilotto S, Tedesco I, Laratta B, Russo GL 
(2012) Dietary polyphenols in cancer prevention: the example of the 
flavonoid quercetin in leukemia. Ann NY Acad Sci 1259 : 95–103.
Vlasova II, Feng WH, Goff JP, Giorgianni A, Do D, Gollin SM, Lewis 
DW, Kagan VE, Yalowich JC (2011) Myeloperoxidase-dependent 
oxidation of etoposide in human myeloid progenitor CD34+ cells. 
Mol Pharmacol 79: 479–487.
Whitlock JA, Greer JP, Lukens JN (1991) Epipodophyllotoxin related 
leukemia. Identification of a new subset of secondary leukemia. 
Cancer 68: 600–604.
Wiczkowski W, Romaszko J, Bucinski A, Szawara-Nowak D, Honke 
J, Zielinski H, Piskula MK (2008) Quercetin from shallots (allium 
cepa l. var. aggregatum) is more bioavailable than its glucosides. J Nutr 
138: 885–888.
Yuan Z, Long Ch, Junming T, Qihuan L, Youshun Z, Chan Z (2012) 
Quercetin-induced apoptosis of HL-60 cells by reducing PI3K/Akt. 
Mol Biol Rep 39: 7785–7793.
